GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Short Interest

Equillium (LTS:0A4D) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Equillium Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Equillium's Short Interest

For the Biotechnology subindustry, Equillium's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Equillium's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Short Interest distribution charts can be found below:

* The bar in red indicates where Equillium's Short Interest falls into.


Equillium (LTS:0A4D) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Short Interest
Comparable Companies
PMCB TCRT FBRX IGC AKTX AVTX MYMD KALA ENTX INDP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
EQ:USA 0FY:Germany
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Website
https://www.equilliumbio.com
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (LTS:0A4D) Headlines

No Headlines